Filtered By:
Condition: Heart Failure
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 331 results found since Jan 2013.

The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
Abstract: Background: Current guidelines recommend intensive low-density lipoprotein (LDL) cholesterol lowering with statins, with a target of 70mg/dL (1.81mmol/L) LDL cholesterol for those with a very high risk of coronary artery events. However, there is no multicenter study assessing the effect of intensive lipid-lowering therapy with statins on acute coronary syndrome (ACS) in a Chinese population with low baseline LDL cholesterol levels.Methods and results: Patients (n=1355) with ACS were treated with a moderate dose of statin (atorvastatin 10 mg/d, or equivalent dose of other statins, n=675) or with an intensive dose...
Source: Atherosclerosis - March 20, 2014 Category: Cardiology Authors: Shui-ping Zhao, Bi-lian Yu, Dao-quan Peng, Yong Huo Tags: Clinical & Population Research – Intervention Source Type: research

Adherence to Guideline-Recommended Therapy Is Associated With Decreased Major Adverse Cardiovascular Events and Major Adverse Limb Events Among Patients With Peripheral Arterial Disease Heart Failure
Conclusions In patients with claudication or CLI, combination treatment with four guideline-recommended therapies is associated with significant reductions in MACE, MALE, and mortality.
Source: JAHA:Journal of the American Heart Association - April 10, 2014 Category: Cardiology Authors: Armstrong, E. J., Chen, D. C., Westin, G. G., Singh, S., McCoach, C. E., Bang, H., Yeo, K.-K., Anderson, D., Amsterdam, E. A., Laird, J. R. Tags: Heart Failure Source Type: research

Statins do not improve cardiovascular outcomes for dialysis patients
Commentary on: Palmer SC, Navaneethan SD, Craig JC, et al.. HMG CoA reductase inhibitors (statins) for dialysis patients: a systematic review and meta-analysis. Cochrane Database Syst Rev 2013;(9):CD004289. Context Chronic kidney disease affected nearly 19 million people in the USA, with incidence increasing globally at an annual rate of 8%, most of which were unrecognised or undiagnosed. Cardiovascular events are common among patients with chronic kidney disease and highest in dialysis patients. While dialysis patients experience a high prevalence of traditional risk factors for cardiovascular disease (CVD), such as hyper...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Olyaei, A. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Neuromuscular disease, Stroke, Hypertension, Obesity (nutrition), Ischaemic heart disease, Unwanted effects / adverse reactions, Renal medicine, Musculoskeletal syndromes Source Type: research

Cardiovascular Risk Assessment Before and After Kidney Transplantation
Cardiovascular disease (CVD) is the leading cause of death in dialysis patients and the most common cause of death and allograft loss among kidney transplant recipients. End-stage renal disease (ESRD) is associated with an increased incidence and prevalence of a wide range of CVDs including coronary artery disease, stroke, congestive heart failure, atrial fibrillation, sudden cardiac death, pulmonary hypertension, and valvular heart disease. CVD risk factors are very common in patients with ESRD, and most patients have multiple risk factors. Kidney transplantation is the treatment of choice for patients with ESRD, as a suc...
Source: Cardiology in Review - June 6, 2014 Category: Cardiology Tags: Review Articles Source Type: research

Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
Conclusions Use of ACEI/ARB was not associated with better outcomes in stable CAD outpatients without HF. The benefit of ACEI/ARB seen in randomized clinical trials was not replicated in this large contemporary cohort, which questions their value in this specific subset.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Sorbets, E., Labreuche, J., Simon, T., Delorme, L., Danchin, N., Amarenco, P., Goto, S., Meune, C., Eagle, K. A., Bhatt, D. L., Steg, P. G. Tags: Coronary artery disease Source Type: research

Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial
Conclusion In subjects with TRH, intensive lipid lowering with atorvastatin 80 mg is associated with a significant reduction in cardiovascular events.
Source: European Heart Journal - July 15, 2014 Category: Cardiology Authors: Bangalore, S., Fayyad, R., Laskey, R., DeMicco, D., Deedwania, P., Kostis, J. B., Messerli, F. H., Treating to New Targets Steering Committee and Investigators Tags: Heart failure/cardiomyopathy Source Type: research

Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases.
Abstract Growing evidence indicates that overproduction of reactive oxygen species (ROS) plays a prominent role in the development of cardio- and cerebro-vascular diseases. Among the mechanisms identified to produce oxidative stress in the vascular wall, those mediated by membrane-bound NAD(P)H oxidases represents a major one. NAD(P)H oxidases are a family of enzymes that generate ROS both in phagocytic and non-phagocytic cell types. Vascular NAD(P)H oxidase contains the membrane-bound subunits Nox1, Nox2 (gp91phox), Nox4 and p22phox, the catalytic site of the oxidase, and the cytosolic components p47phox and p67p...
Source: Current Drug Targets - October 27, 2014 Category: Drugs & Pharmacology Authors: Carrizzo A, Forte M, Lembo M, Formisano L, Puca AA, Vecchione C Tags: Curr Drug Targets Source Type: research

Particularities in coronary revascularization in elderly patients presenting with ST segment elevation acute myocardial infarction (STEMI)
Publication date: August 2014 Source:Cor et Vasa, Volume 56, Issue 4 Author(s): Maria Dorobanţu , Lucian Câlmâc , Andrada Bogdan , Vlad Bătăilă , Bogdan Drăgoescu , Andrei Radu , Mugur Marinescu , Şerban Arvanitopol , Gabriel Tatu-Chiţoiu , Rodica Niculescu Nowadays, ST elevation acute myocardial infarction (STEMI) is seen with greater incidence in older patients. Current guidelines recommend an immediate invasive evaluation and eventually primary percutaneous coronary intervention (PCI) in all STEMI patients regardless of age. Nevertheless, data in literature show a significant underuse of interventional treatm...
Source: Cor et Vasa - November 1, 2014 Category: Cardiology Source Type: research

Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus
Conclusions PN is associated with increased risk for a first cardiovascular event among individuals with diabetes.
Source: Heart - November 9, 2014 Category: Cardiology Authors: Brownrigg, J. R. W., de Lusignan, S., McGovern, A., Hughes, C., Thompson, M. M., Ray, K. K., Hinchliffe, R. J. Tags: Drugs: cardiovascular system, Heart failure, Hypertension, Acute coronary syndromes, Diabetes, Metabolic disorders, Tobacco use Cardiac risk factors and prevention Source Type: research

Assessment of Lipophilic vs. Hydrophilic Statin Therapy in Acute Myocardial Infarction.
Conclusions:On 2-year comparison of hydrophilic and lipophilic statins there was no significant difference in prevention of secondary cardiovascular outcome. PMID: 25392071 [PubMed - as supplied by publisher]
Source: Circulation Journal - November 12, 2014 Category: Cardiology Authors: Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, Sakurai S, Kagoshima M, Tomita T, Miyashita Y, Koyama J, Ikeda U Tags: Circ J Source Type: research

Myocardial infarction in older than 75 years: An increasing population. CASTUO study
Conclusions Patients older than 75 years with acute myocardial infarction had lower survival and were treated with fewer beta-blockers, statins and angioplasty, indications that are associated with lower mortality.
Source: Revista Clinica Espanola - January 16, 2015 Category: Internal Medicine Source Type: research

Does preoperative statin therapy prevent postoperative atrial fibrillation in patients undergoing cardiac surgery?
In conclusion, the available evidence suggests that preoperative statin therapy in patients undergoing elective cardiac surgery is associated with the following: (1) a lower incidence and risk of developing postoperative AF, (2) reduced stroke, (3) a shorter hospital stay and (4) reduced levels of inflammatory markers postoperatively. However, while the evidence supports the use of statins preoperatively, the optimal duration, dose and type of statin cannot be concluded from this review.
Source: Interactive CardioVascular and Thoracic Surgery - February 12, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Goh, S. L., Yap, K. H., Chua, K. C., Chao, V. T. T. Tags: Congestive Heart Failure, Electrophysiology - arrhythmias, Molecular biology Adult Cardiac Source Type: research

Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual‐level reanalysis of CORONA and GISSI‐HF
ConclusionThis individual‐level reanalysis of two landmark trials demonstrates a small but statistically significant decreased risk for MI among patients with ischaemic HF randomized to rosuvastatin vs. placebo. Rosuvastatin appears to be effective in preventing MI in ischaemic HF patients not already on statins.
Source: European Journal of Heart Failure - February 1, 2015 Category: Cardiology Authors: Matthew J. Feinstein, Pardeep Jhund, Joseph Kang, Hongyan Ning, Aldo Maggioni, John Wikstrand, John Kjekshus, Luigi Tavazzi, John McMurray, Donald M. Lloyd‐Jones Tags: Original Article Source Type: research

CHADS2 and CHA2DS2-VASc Scoring Systems for Predicting Atrial Fibrillation following Cardiac Valve Surgery
by Liang Yin, Xinyu Ling, Yufeng Zhang, Hua Shen, Jie Min, Wang Xi, Jing Wang, Zhinong Wang Objective Clinical use of CHADS2 and CHA2DS2-VASc scoring systems for predicting AF following cardiac surgery have been reported in previous studies and demonstrated well-validated predictive value. We sought to investigate whether the two scoring systems are effective for predicting new-onset of AF following cardiac valve surgery and to demonstrate its potential utility of clinical assessment. Methods Medical records of all patients underwent cardiac valve surgeries during the period of January 2003 and December 2013 without preope...
Source: PLoS One - April 7, 2015 Category: Biomedical Science Authors: Liang Yin et al. Source Type: research

β-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial
Conclusions β-blocker therapy after CABG is not associated with reductions in angina or cardiovascular events in low-risk patients with preserved LVEF, and may not be systematically indicated in such patients.
Source: Cardiovascular Drugs and Therapy - June 14, 2015 Category: Cardiology Source Type: research